研究課題情報
課題管理番号
21jm0210086h9902
統合プロジェクト(二期)

シーズ開発・研究基盤プロジェクト<第二期>

事業名

医療分野国際科学技術共同研究開発推進事業

タグ(2021)

研究の性格: 生命・病態解明等を目指す研究

対象疾患: その他

疾患領域: 感染症

開発目的: 予防・健康 ,  診断 ,  治療 ,  生活の質<QOL>

タグ(2020)

研究の性格: 研究基盤及び創薬基盤の整備研究<創薬技術・ICT基盤・プラットフォーム関係含む>

対象疾患: その他

疾患領域: 感染症

開発目的: 診断 ,  治療

代表研究機関
国立大学法人東京大学
研究代表者

(2021) MOI MENG LING, 国立大学法人東京大学, 大学院医学系研究科・教授

(2020) MOI MENG LING, 国立大学法人長崎大学, 熱帯医学研究所 教授

研究期間
2020年度 - 2021年度
課題への総配分額
7,033 千円
研究概要(2021)
For FY2021, we will continue COVID-19 patient sample collection and characterization between Japan, Vietnam and the Philippines. Vietnam and Philippines researchers will lead in identification of SARS-CoV-2 clusters and longitudinal sample collection. Next, Japanese counterpart will lead in local sample collection, virological and immunological characterization of the samples, and will co-lead with the USA counterpart to analyze the transcriptional and epigenetic signatures of SARS-CoV-2 infection. We will measure the neutralization titers against SARS-CoV-2 in acute and convalescent samples via standard Vero cell-based plaque reduction neutralization test (PRNT) assays to assess whether levels of cross-reactive anti-CoV and SARS-CoV-2-specific neutralizing Abs correlate with clinical outcomes, using standard assays and FcγR-expressing cell assay system.
研究概要(2020)
For FY2020, we will start with COVID-19 patient sample collection and characterization in Vietnam and the Philippines. Vietnam and Philippines researchers will lead in identification of SARS-CoV-2 clusters and longitudinal sample collection. Next, Japanese counterpart will lead in virological and immunological characterization of the samples, and will co-lead with the USA counterpart to analyze the transcriptional and epigenetic signatures of SARS-CoV-2 infection. Briefly, we will measure the neutralization titers against SARS-CoV-2 in acute and convalescent samples via standard Vero cell-based plaque reduction neutralization test (PRNT) assays to assess whether levels of cross-reactive anti-CoV and SARS-CoV-2-specific neutralizing Abs correlate with clinical outcomes, using standard assays and ACE-2/FcγR-expressing system.
研究成果情報
2021
2020